**C-X-C motif chemokine receptor 4 (CXCR4)** is a widely studied transmembrane chemokine receptor involved in tumor growth, metastasis, and hematopoietic stem cell or progenitor homing and retention in hematopoietic sites (2). In addition, previous studies have shown CXCR4 overexpression in more than 30 different tumor entities (3–5), including multiple myeloma (6), diffuse large B-cell lymphoma (7), and small cell lung cancer (8). Recently, the radiolabeled CXCR4-targeted ligand $^{68}$Ga-pentixafor has been developed for PET imaging and has been shown to noninvasively visualize CXCR4 expression in multiple hematologic malignancies as well as inflammatory disease conditions in vivo (3,5,7,9,10). However, there is limited knowledge regarding imaging features of MPNs.

The aim of this proof-of-principle study was to assess the feasibility of noninvasive CXCR4-directed imaging with PET/CT in patients with MPNs.

**MATERIALS AND METHODS**

Subjects and Study Design

Between April 2015 and May 2017, 12 patients (6 men and 6 women; age range, 37–73 y; mean age, 58.2 ± 9.1 y) with MPNs underwent molecular imaging with $^{68}$Ga-pentixafor PET/CT. All patients had a clinically, molecularly, or histologically confirmed myeloproliferative disorder (primary myelofibrosis, $n = 4$; polycythemia vera, $n = 2$; essential thrombocythemia, $n = 6$). Detailed characteristics of the patient cohort are shown in Table 1. Five nononcologic patients (3 men and 2 women; mean age, 59 ± 8 y) were included as a control group (detailed in the supplemental methods; supplemental materials are available at http://jnm.snmjournals.org).

PET/CT Imaging

$^{68}$Ga-pentixafor was prepared as previously described (11) (detailed in the supplemental methods). After injection of $^{68}$Ga-pentixafor (median, 130 MBq; range, 74–190 MBq), all PET/CT scans were performed on a dedicated PET/CT scanner (Biograph mCT 64; Siemens Medical Solutions) using standard acquisition and reconstruction protocols (detailed in the supplemental methods).

Image Analysis

PET/CT scans were visually assessed by 2 board-certified nuclear medicine physicians. First, a visual inspection of scans for elevated intramedullary tracer uptake (higher than mediastinal blood pool) was performed. For semiquantitative analysis, $S_UV_{mean}$ was determined as follows: in an initial step, transaxial slices in the middle of the L2–L4 vertebral bodies were selected. Next, tracer uptake in each vertebral body was determined by placing a region of interest of 10-mm diameter in the center of each vertebra. The individual overall $S_UV_{mean}$ of (L2–L4) was calculated as the mean of the respective $S_UV_{mean}$ of...
these 3 regions of interest. For assessment of the spleen, a region of interest with a diameter of 4 cm was used. Background activity was measured by placing a 15-mm region of interest in the center of the right atrium (blood pool SUV). Mean tumor-to-blood ratios were calculated by dividing the L2-L4 SUVmean by the blood pool SUV.

Splenic volumes were assessed by means of CT.

Immunohistochemistry Stainings of Patient Biopsy Material

Immunohistochemistry stainings were performed on 10% formalin-fixed, paraffin-embedded BM biopsy samples from 9 of 12 MPN patients (detailed in the supplemental methods).

Statistical Analysis

Statistical analyses were performed using Prism software (version 6.0; GraphPad Software, Inc.). Results are shown as mean ± SD or median and range as indicated. All statistical tests were performed 2-sided, and a P value of less than 0.05 was considered to indicate statistical significance.

RESULTS

CXCR4-directed PET imaging with 68Ga-pentixafor was visually positive in all patients. 68Ga-pentixafor PET/CT depicted significantly increased tracer uptake both in the BM and in extramedullary hematopoietic sites as compared with controls, with an SUVmean of 4.44 ± 1.3 in the BM (controls, 2.67 ± 0.41; P = 0.01) and an SUVmean of 6.45 ± 2.34 in the spleen (controls, 4.44 ± 1.24; P = 0.09) (example given in Fig. 1). Individual imaging results can be found in Supplemental Tables 1 and 2, respectively.

No significant differences were observed between the SUVmean of the different subtypes of MPN (Table 2). Patients with JAK2V617F-positive or CALR-positive mutations did not show higher BM uptake than JAK2V617F-negative patients (r = 0.19, P = not statistically significant). Additional BM biopsies were available in 9 of 12 patients and confirmed moderate to strong CXCR4 expression in dysplastic cells of the megakaryocytic lineage in all samples (Supplemental Fig. 1).

Three patients additionally underwent follow-up CXCR4-directed PET/CT after a median of 6 mo (range, 4–7 mo) after treatment initiation with ruxolitinib (patients 1 and 6) and hydroxyurea (patient 5). In these patients, initially high tracer accumulation in the spleen and BM (with an SUVmean of 6.12 ± 2.15, 3.60 ± 1.14, and 4.10 ± 0.32, respectively) declined (SUVmean: BM, 3.97 vs. 2.86; spleen, 7.72 vs. 4.89) in response to treatment (Fig. 2). Furthermore, the decrease in SUVmean after treatment corresponded with a spleen volume reduction and normalization of hemoglobin, peripheral leukocyte count,

### TABLE 1

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Diagnosis</th>
<th>Disease stage</th>
<th>Mutation</th>
<th>Splenomegaly and splenic volume</th>
<th>Treatment</th>
<th>Follow-up PET/CT</th>
<th>CSCR4 IHC staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>73</td>
<td>PV</td>
<td>Initial diagnosis</td>
<td>JAK2 V617F</td>
<td>Yes (532 cm³)</td>
<td>Ruxolitinib</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>66</td>
<td>ET</td>
<td>Initial diagnosis</td>
<td>JAK2 V617F</td>
<td>No (226 cm³)</td>
<td>None</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>37</td>
<td>ET</td>
<td>Initial diagnosis</td>
<td>CALR</td>
<td>Yes (260 cm³)</td>
<td>None</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>51</td>
<td>ET</td>
<td>Stable disease</td>
<td>JAK2 V617F</td>
<td>No (228 cm³)</td>
<td>Anagrelide</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>60</td>
<td>ET</td>
<td>Initial diagnosis</td>
<td>CALR</td>
<td>Yes (450 cm³)</td>
<td>Hydroxyurea</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>64</td>
<td>PMF</td>
<td>Initial diagnosis</td>
<td>JAK2 V617F</td>
<td>Yes (689 cm³)</td>
<td>Ruxolitinib</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>58</td>
<td>PV</td>
<td>Stable disease</td>
<td>JAK2 V617F</td>
<td>No (280 cm³)</td>
<td>Hydroxyurea</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>62</td>
<td>PMF</td>
<td>Progressive disease</td>
<td>JAK2 V617F</td>
<td>Yes (508 cm³)</td>
<td>Ruxolitinib</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>42</td>
<td>PMF</td>
<td>Initial diagnosis</td>
<td>None detected</td>
<td>No (250 cm³)</td>
<td>None</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>63</td>
<td>ET</td>
<td>Stable disease</td>
<td>JAK2 V617F</td>
<td>Yes (625 cm³)</td>
<td>Hydroxyurea</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>58</td>
<td>PMF</td>
<td>Initial diagnosis</td>
<td>JAK2 V617F</td>
<td>No (214 cm³)</td>
<td>None</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>52</td>
<td>ET</td>
<td>Stable disease</td>
<td>None detected</td>
<td>No (180 cm³)</td>
<td>Anagrelide</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

IHC = immunohistochemistry; PV = polycythemia vera; ET = essential thrombocytemia; PMF = primary myelofibrosis; CALR = calreticulin.
thrombocyte count, and lactate dehydrogenase level (Supplemental Table 2).

DISCUSSION

Although PET/CT imaging is widely used for the diagnosis, staging, and response assessment of various types of hematologic malignancies (12), it is not routinely used in patients with MPNs. Currently, with the diagnosis being based solely on the assessment of clinical, hematologic, histopathologic, and genetic parameters (1), no imaging technique is established for the assessment of BM involvement. Here, we present the first (to our knowledge) proof-of-principle study investigating the in vivo application of 68Ga-pentixafor in patients with MPNs. We demonstrate the feasibility of 68Ga-pentixafor PET/CT to noninvasively detect and quantify the extent of BM involvement, with MPN patients demonstrating significantly higher tracer uptake in the BM and extramedullary hematopoietic sites than was seen in nonmalignant controls. With SUV\textsubscript{mean} ranging between 2.9 and 7.4, the intensity of 68Ga-pentixafor uptake in the BM of MPN patients was similar to that previously reported for BM involvement in patients with chronic lymphatic leukemia (13) and acute myeloid leukemia (14).

Interestingly, in our small cohort, the highest tracer accumulation was detected in the BM of a patient with essential thrombocythemia at the time of initial diagnosis. However, further research to establish and validate cutoffs for both detection of BM involvement and differentiation between various disease types is still needed.

Our findings are consistent with the concept of MPNs as chronic inflammatory diseases (15) in conjunction with an impaired microenvironment that favors malignant over normal hematopoiesis through profound changes in the BM stromal compartment and increased cytokine levels. Interestingly, megakaryocytes have been shown to contribute to MPN pathology and to be a major driver of BM fibrosis (16). In line with that observation, our immunohistochemistry data show CXCR4 expression predominantly on the surface of dysplastic cells of the megakaryocytic lineage. In this context, the extent of CXCR4 uptake may, therefore, also serve as a prognostic factor to further stratify MPN patients.

We monitored 3 newly diagnosed MPN patients (3 of our total of 12 patients) over a median of 6 mo after treatment initiation, showing that CXCR4 uptake determined by 68Ga-pentixafor PET/CT might correlate with treatment response. The extent of both BM and splenic uptake (SUV\textsubscript{mean}: BM, 3.97 vs. 2.86; spleen, 7.72 vs. 4.89) decreased with treatment initiation. Interestingly, tracer uptake in BM and spleen correlated with hematologic parameters and splenic volume. The reduction in SUV\textsubscript{mean} after treatment correlated with normalization of hemoglobin, peripheral leukocyte count, thrombocyte count, and lactate dehydrogenase. Whereas recent data suggest additional utility for CXCR4-directed PET/CT imaging for response assessment in hematologic malignancies such as extranodal marginal zone lymphoma (17) or central nervous system B-cell lymphoma (18), the extent to which 68Ga-pentixafor PET/CT can be used for response assessment in MPNs needs to be investigated in future prospective studies.

![FIGURE 1. Display of patient (patient 6) with primary myelofibrosis. 68Ga-pentixafor PET/CT (maximum-intensity projections) depicts significantly increased tracer uptake in BM as well as spleen compared with control group.](image)

TABLE 2

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All patients (n = 12)</th>
<th>Primary myelofibrosis (n = 4)</th>
<th>Essential thrombocythemia (n = 6)</th>
<th>Polycythemia vera (n = 2)</th>
<th>Controls (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM SUV\textsubscript{mean}</td>
<td>4.44 ± 1.3 (2.9–7.4)</td>
<td>5.48 ± 0.80 (4.2–6.1)</td>
<td>4.01 ± 1.40 (2.9–7.4)</td>
<td>3.92 ± 0.22 (3.7–4.1)</td>
<td>2.67 ± 0.41 (2.3–3.3)</td>
</tr>
<tr>
<td>Spleen SUV\textsubscript{mean}</td>
<td>6.45 ± 2.34 (3.5–12.5)</td>
<td>6.12 ± 0.76 (4.6–6.4)</td>
<td>7.37 ± 2.53 (4.1–12.5)</td>
<td>4.72 ± 1.25 (3.5–6.0)</td>
<td>4.44 ± 1.24 (2.9–5.4)</td>
</tr>
</tbody>
</table>

Data are SUV\textsubscript{mean}. Values are provided as mean ± SD (range).
Our pilot observation suffers from several limitations. The radiation exposure associated with PET/CT prevented the use of a control group of healthy individuals. Instead, we included Conn adenoma patients as a control group who received CXCR4 PET/CT imaging as part of their endocrinologic investigation (19), and $^{68}$Ga-pentixafor uptake in other controls might be even lower than in our endocrinologic control group. However, when compared with previously reported upper limits of physiologic BM uptake measurements in cancer patients without BM involvement, values agree broadly with our study ($SUV_{max}$: BM for pancreatic adenocarcinoma, 1.7; BM for mucosa-associated lymphoid tissue lymphoma, 2.3) (13). Furthermore, although immunohistochemical analysis could demonstrate CXCR4 expression in all BM biopsies, CXCR4 expression was relatively low and did not clearly correspond with the intensity of the PET signal. However, surface expression of CXCR4 is a dynamic process and can be influenced by therapeutic interventions (20).

CONCLUSION

To our knowledge, our data are the first to demonstrate that CXCR4-directed imaging with $^{68}$Ga-pentixafor PET/CT is feasible to visualize and quantify disease involvement in MPN patients. Further evaluation in larger, prospective studies is warranted to determine the clinical impact in primary staging and response assessment and to evaluate the potential for a theranostic approach.

DISCLOSURE

Hans-Jürgen Wester is the founder and shareholder of Scintomics. No other potential conflict of interest relevant to this article was reported.

FIGURE 2. Response assessment with CXCR4-directed PET/CT imaging (maximum-intensity projections). Shown is example of therapy-induced CXCR4 downregulation in patient with essential thrombocythemia (patient 5).

REFERENCES

17. Kraus et al. CXCR4 imaging in MPN - Kraus et al. 99

QUESTION: Is CXCR4-directed PET imaging with $^{68}$Ga-pentixafor feasible to visualize and quantify disease involvement in MPNs?

PERTINENT FINDINGS: This retrospective analysis revealed that CXCR4-directed imaging is positive in all investigated patients and showed a significantly higher tracer uptake in the BM of patients with MPNs.

IMPLICATIONS FOR PATIENT CARE: CXCR4-directed PET imaging with $^{68}$Ga-pentixafor is feasible to noninvasively detect and quantify the extent of BM involvement in patients with MPNs.

KEY POINTS

1. CXCR4 imaging with $^{68}$Ga-pentixafor feasible to non-invasively detect and quantify the extent of BM involvement in patients with MPNs.

2. Further evaluation in larger, prospective studies is warranted to determine the clinical impact in primary staging and response assessment and to evaluate the potential for a theranostic approach.

3. Hans-Jürgen Wester is the founder and shareholder of Scintomics. No other potential conflict of interest relevant to this article was reported.

4. CXCR4 imaging in MPN - Kraus et al. 99